# Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

> **NCT06060886** · PHASE4 · UNKNOWN · sponsor: **Consorcio Centro de Investigación Biomédica en Red (CIBER)** · enrollment: 244 (estimated)

## Conditions studied

- Schizophrenia
- Treatment-resistant Schizophrenia
- Side Effect
- Lipid Metabolism Disorders
- Diabetes
- NAFLD
- Psychosis

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Paliperidone

## Key facts

- **NCT ID:** NCT06060886
- **Lead sponsor:** Consorcio Centro de Investigación Biomédica en Red (CIBER)
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2023-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06060886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06060886, "Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06060886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*